Calcitonin Dosing for CRPS Treatment
Calcitonin is not routinely recommended for CRPS treatment based on current evidence, but when used, the typical dose studied is 200 IU intranasally daily or 20 units intramuscularly weekly, though efficacy remains questionable and side effects are substantial.
Evidence Assessment
The FDA-approved calcitonin dosing is 200 International Units per day intranasally for osteoporosis 1, but this indication does not include CRPS. The FDA label contains no mention of CRPS as an approved indication.
The 2010 ASA/ASRA chronic pain guidelines 2 do not mention calcitonin at all for CRPS management, instead recommending lumbar sympathetic blocks or stellate ganglion blocks as components of multimodal CRPS treatment.
Research Evidence on Calcitonin for CRPS
Dosing Regimens Studied:
Intranasal route: 200 IU daily has been studied 3, showing no significant benefit over paracetamol plus physical therapy in acute CRPS type 1. All parameters improved in both groups, but calcitonin provided no additional advantage (p>0.05).
Intramuscular route: 20 units of elcatonin weekly was studied for CRPS prevention after stroke 4, showing reduced CRPS incidence (12.5% vs 57.1% in controls) when started ≤4 weeks post-stroke, but prophylactic effects were weak when started >6 weeks after stroke.
Subcutaneous route: 0.5 mg human calcitonin daily for 8 weeks was studied 5, showing only statistically significant improvement in edema reduction (p<0.01) compared to controls. Critically, 83% of patients experienced severe side effects (mostly gastrointestinal), and therapy had to be discontinued in 13% of cases.
Critical Limitations
Lack of High-Quality Evidence:
Recent Cochrane overview 6 found no high-certainty evidence for any CRPS intervention, and did not identify calcitonin as having sufficient evidence to recommend. The 2023 evidence-based review 7 does not list calcitonin among recommended therapeutic approaches.
Side Effect Burden:
The subcutaneous formulation causes severe gastrointestinal side effects in the majority of patients 5, making it poorly tolerated despite marginal benefits limited to edema reduction.
Conflicting Results:
One study showed benefit for prevention 4, while treatment studies showed minimal to no benefit 3, 5.
Clinical Recommendation
Do not use calcitonin as a routine treatment for established CRPS. If considering it despite limited evidence:
- For prevention in high-risk stroke patients: 20 units intramuscularly weekly, started within 4 weeks of stroke 4
- For treatment (not recommended): 200 IU intranasally daily 3 has the best tolerability profile, though efficacy is unproven
Instead, prioritize: Sympathetic nerve blocks (stellate ganglion or lumbar sympathetic blocks) as part of multimodal therapy 2, physical therapy, gabapentinoids, and bisphosphonates (which have low-certainty evidence but better support than calcitonin) 6.
Key Pitfall:
The FDA approval of calcitonin for osteoporosis at 200 IU daily does not translate to CRPS efficacy. The malignancy risk associated with long-term calcitonin use 1 further argues against its use in a condition where evidence of benefit is lacking.